Lutetium 177 PSMA - Problems with the Vision Trial

  Рет қаралды 4,268

Vinay Prasad MD MPH

Vinay Prasad MD MPH

Күн бұрын

Пікірлер: 14
@Yotachic
@Yotachic 3 жыл бұрын
Love it Vinay! As an Oncology Clinical Research Coordinator I see this all the time. And people don’t give patients enough credit...they can sniff out when things might not be optimal for their care when it comes to these trials. Love your book and all your clinical trial and paper reviews! Keep it up!
@barbaraberwick8993
@barbaraberwick8993 4 ай бұрын
😂 I loved the coffee comment. Thank you Dr. Prasad. Please continue pointing out all these horrendous studies.
@photon1972
@photon1972 2 жыл бұрын
"Horrific amounts of money" 100% true! $240K for a course of treatment. Thanks.
@kabauny
@kabauny 6 ай бұрын
Med onc Fellow here. Love the criticism!
@dethsor666
@dethsor666 2 жыл бұрын
Great presentation, when I first looked into it, I thought it was dodgy too. Comparing a therapeutic vs. doing nothing seemed quite dodgy. A/Prof Prasad, given the interesting methodology used for the VISION trial. What do you take of the FDA approving the Novartis Lu-PSMA radiopharmaceutical.
@velibakalov7732
@velibakalov7732 3 жыл бұрын
Great review!
@laurac1635
@laurac1635 2 жыл бұрын
Dr. Prasad thank you for your video. All too often in Oncology we look at the final reports and do not deep dive into the trials and realize that the overall benefits touted are not always that impressive or scientifically sound.
@fabdoc
@fabdoc 10 ай бұрын
Great video. Can you talk about PSMAfore trial please.
@doctornebula
@doctornebula 8 ай бұрын
I suspect that the high drop out rate in the control arm was mainly due to not being assigned to Lutetium-177 and less about knowledge of a deficient control arm. This new therapy had gotten a lot of exposure in the prostate cancer community as it had been used in Germany for 10 years prior to the trial. These CRPC patients went into the trial praying they would get Lu-177 and half said nope when assigned to the control arm.
@gumbycat5226
@gumbycat5226 Жыл бұрын
That was most useful. I am interested in this protocol because it makes so much sense but as you've just shown, their so-called trial is at best a farce. Well begun is half done, that's one of my mottos, and this paper certainly does not begin the introduction of this novel treatment in any way that can be considered either well or ethical.
@ducciopappadopulo4217
@ducciopappadopulo4217 Жыл бұрын
all great but what's the error on that 0.32%?
@jonikaweerasekare2084
@jonikaweerasekare2084 2 жыл бұрын
Nice to see some non-covid stuff as someone going into IM!
Lutetium-177: PSMA Guided Treatment | #ProstateCancer | #MarkScholzMD | #PCRI
11:01
Prostate Cancer Research Institute
Рет қаралды 17 М.
My MEAN sister annoys me! 😡 Use this gadget #hack
00:24
JOON
Рет қаралды 2,8 МЛН
ЛУЧШИЙ ФОКУС + секрет! #shorts
00:12
Роман Magic
Рет қаралды 26 МЛН
ROSÉ & Bruno Mars - APT. (Official Music Video)
02:54
ROSÉ
Рет қаралды 295 МЛН
10 Things We can See in Health Care in a Trump Administration
17:33
Vinay Prasad MD MPH
Рет қаралды 37 М.
Bill Eddy: How to Deal With High Conflict People
2:39:22
Andrew Huberman
Рет қаралды 287 М.
UROwebinar: New treatment options in mCRPC
1:04:24
European School of Urology
Рет қаралды 1 М.
PSMA Scans & Pluvicto (lutetium-177) in 2022 | Geoffrey Johnson, MD, PhD | PCRI Conference 2022
1:10:05
177 Lu PSMA Treatment for Prostate Cancer (Update: FDA approved on 3/23/22)
7:09
Society of Nuclear Medicine and Molecular Imaging
Рет қаралды 6 М.
My MEAN sister annoys me! 😡 Use this gadget #hack
00:24
JOON
Рет қаралды 2,8 МЛН